Zealand Pharma shares fell 11.02 percent to 424.50 Danish crowns on Thursday. The trigger was convincing study data from Eli Lilly for an experimental obesity drug that achieved an average weight loss of 20.1 percent in patients. These results immediately put pressure on competitors in the pharmaceutical sector.
Eli Lilly sets new standards
Eli Lilly’s midstage data changes the playing field for all companies working on obesity treatments – including Zealand Pharma. Nordnet analyst Per Hansen stresses that these results could put particular pressure on Zealand Pharma, whose own research data for petrilintide in collaboration with Roche is still pending.
- Eli Lilly’s breakthrough: 20.1 percent weight loss in midstage study sets new benchmark
- Zealand Pharma’s hopefuls: The amylin analog petrilintide targets 15-20 percent weight loss
- Time delay: Phase IIb data for Zealand Pharma/Roche are not expected until the first half of 2026
Can Petrilintide still convince?
Despite the negative market reaction, some analysts remain confident. Jefferies analysts believe Zealand Pharma and Roche’s Amylin analog could still achieve 15-20 percent weight loss in the long term. However, the brokerage admits that a “best-in-class” narrative will be difficult to market until comparable data from Zealand Pharma’s trials are available.
Clear downward trend confirmed
The Zealand Pharma share is currently trading at 427.00 Danish kroner and is therefore trading around 9.16 percent below its 200-day average – a clear downward signal. The market will closely monitor the company’s pipeline developments, particularly in the area of obesity treatments. The upcoming quarters of key clinical milestones will be critical to Zealand Pharma’s long-term competitive position.
Advertisement
Zealand Pharma share: buy or sell?! New Zealand Pharma analysis from November 9th provides the answer:
The latest Zealand Pharma figures speak loudly: there is an urgent need for action for Zealand Pharma shareholders. Is it worth getting started or should you sell? In the current free analysis from November 9th you will find out what to do now.
Zealand Pharma: buy or sell? Read more here…
